1/63
ONCOL 309 - Clinical Oncology I. University of Alberta
Name | Mastery | Learn | Test | Matching | Spaced |
---|
No study sessions yet.
Bladder TD5/5 Max dose and endpoint
65 Gy
contracture/volume loss
Esophagus TD5/5 endpoint and max dose
55 Gy
stricture
Femoral Heads TD5/5 max dose and endpoint
52 Gy
necrosis
Heart TD5/5 max dose and endpoint (1/3)
60 Gy
pericarditis
Large Bowel TD5/5 max dose and endpoint
45 Gy
obstruction, ulcertaion, fistula, perforation
Liver TD5/5 max dose and endpoint
30 Gy
liver failure
Lungs TD5/5 max dose and endpoint for 1/3
45 Gy
pneumonitis
Lungs TD5/5 max dose and endpoint for 2/3
30 Gy
pneumonitis
Lungs TD5/5 max dose and endpoint for 3/3
17 Gy
pneumonitis
Kidney TD5/5 max dose and endpoint for 1/3
50 Gy
nephritis
Kidney TD5/5 max dose and endpoint for 2/3
30 Gy
nephritis
Kidney TD5/5 max dose and endpoint for 3/3
23 Gy
nephritis
Rectum TD5/5 max dose and endpoint
60 Gy
severe necrosis, stenosis, fistula
Colon TD5/5 max dose and endpoint
45 Gy
obstruction / perforation
Skin TD 5/5 Max dose and endpoint
55 Gy in 100 cm2
telangietasia
Spinal cord TD5/5 max dose and endpoint for 10 cm
10 cm = 50 Gy
myelitis, necrosis
Spinal cord TD5/5 max dose and endpoint for 20 cm
20 cm = 47 Gy
myelitis, necrosis
Small bowel (peritoneal cavity) TD5/5 max dose and endpoint
40 Gy
obstruction, perforation
Stomach TD5/5 max dose and endpoint
50 Gy
ulceration, perforation
Ovary TD5/5 max dose and endpoint for 1/3
6-12 Gy
sterilization
Ovary TD5/5 max dose and endpoint for 3/3
2-3 Gy
sterilization
Testis TD5/5 max dose and endpoint for 1/3
2 Gy
sterilization
Testis TD5/5 max dose and endpoint for 3/3
1 Gy
sterilization
Stomach acute dose-tissue response
10 Gy
N+V
Small bowel acute dose-tissue response
20 Gy
diarrhea
Esophagus acute dose-tissue response
20 Gy
esophagitis
skin acute dose-tissue response to 20 Gy
erythema
skin acute dose-tissue response to 30 Gy
dry desquamation
skin acute dose-tissue response to 40 Gy
moist desquamation
bladder acute dose-tissue response
30 Gy
cystitis
liver acute dose-tissue response
25 Gy
acute/chronic hepatitis
kidney acute dose-tissue response
15 Gy
nephrosclerosis
Brain TD5/5 max dose and endpoint
45 Gy
necrosis
Brain stem TD5/5 maxdose and endpoint
50 Gy
necrosis
Optic nerve TD5/5 max dose and endpoint
50 Gy
blindness
Spinal cord TD5/5 max dose and endpoint for 20 cm
47 Gy
myelitis necrosis
parotid TD5/5 max dose and endpoint
32 Gy
xerostomia
Ear TD5/5 max dose and endpoint
55 Gy
chronic serous otitis
Larynx TD5/5 max dose and endpoint
70 Gy
necrosis
Retina TD5/5 max dose and endpoint
45 Gy
blindness
Bone marrow TD5/5 max dose and endpoint for 1/3
25 Gy
aplasia, pancytopenia
Bone marrow TD5/5 max dose and endpoint for 3/3
4.5 Gy
aplasia, pancytopenia
TMJ Mandible TD5/5 max dose and endpoint
60 Gy
decreased function
Lens TD5/5 max dose and endpoint
10 Gy
cataracts
Taste buds acute dose-tissue response
10 Gy
taste changes
salivary glands acute dose-tissue response
10-20 Gy
xerostomia
cervical spinal cord acute dose-tissue response
20-30 Gy
Lhermitte’s sign
numbness or tingling in limbs after neck flexion
oral mucosa acute dose-tissue response
20-30 Gy
mucositis
ear acute dose-tissue response
30 Gy
acute serous otitis
lacrimal gland acute dose-tissue response
40 Gy
dry eye
larynx acute dose-tissue response
45-50 Gy
edema / laryngitis
mandible acute dose-tissue response
60 Gy
trismus
pediatric bone acute dose-tissue response
10 Gy
growth arrest
pediatric lung acute dose-tissue response
15 Gy
pulmonary fibrosis
pediatric testis acute dose-tissue response
0.5-2 Gy
transient oligospermia
pediatric pituitary and hypothalamus acute dose-tissue response
20 Gy
hormone deficits
pediatric cochlea acute dose-tissue response
30 Gy
hearing impairment
serial or parallel: spinal cord
serial
serial or parallel: parotid gland
parallel
serial or parallel: inner/middle ear
parallel
serial or parallel: optic structures
serial
serial or parallel: temporal lobes
serial
serial or parallel: neck skin
parallel
serial or parallel: mandible and TMJ
serial